Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-08-04Clinical Trial Update: PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation
This report summarizes PET-CT imaging findings and preliminary clinical observations from a completed trial involving patients with neuroend…
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Evaluation of Blood Vessel Formation in Endocrine Tumors
The National Cancer Institute-sponsored trial evaluating angiogenesis in endocrine tumors has completed.
-
CLINICAL_TRIALS trial_result · 2017-05-03Clinical Trial Update: 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs) [Phase 1]
A Phase 1 trial evaluating the PET imaging agent 68Ga-DOTATOC for somatostatin receptor–positive neuroendocrine tumors has been terminated.
-
CLINICAL_TRIALS trial_result · 2017-03-21Clinical Trial Update: Best Therapy for Patients With Neuroendocrine Tumors
A clinical trial evaluating therapies for neuroendocrine tumors has completed enrollment; results are not provided in the snippet.
-
CLINICAL_TRIALS trial_result · 2017-03-01Clinical Trial Update: EPO906 in Carcinoid and Other Neuroendocrine Tumors [Phase 2]
Phase 2 trial of EPO906 (irofulven) in carcinoid tumors and other neuroendocrine tumors has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-12-28Clinical Trial Update: Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) [Phase 3]
Phase 3 trial comparing everolimus plus best supportive care to placebo plus best supportive care in patients with advanced neuroendocrine t…
-
CLINICAL_TRIALS withdrawal · 2016-11-08Clinical Trial Update: Gallium-68 DOTATOC for Management of Neuroendocrine Tumors
A clinical trial evaluating Gallium-68 DOTATOC for the management of Neuroendocrine tumors is no longer available.
-
CLINICAL_TRIALS withdrawal · 2016-11-02Clinical Trial Update: 68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial
The expanded access trial of the radiopharmaceutical 68Ga-DOTATOC for imaging neuroendocrine tumors is no longer available.
-
FDA approval · 2016-10-31FDA Approved: NETSPOT — Supplemental Application (Advanced Accelerator Applications USA, Inc)
The FDA approved a supplemental application for NETSPOT (68GA-DOTATATE) submitted by Advanced Accelerator Applications USA, Inc., expanding …
-
CLINICAL_TRIALS trial_result · 2016-10-19Clinical Trial Update: Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors [Phase 1]
A Phase 1 trial assessing the combination of pasireotide and RAD001 (everolimus) in patients with advanced neuroendocrine tumors has complet…
-
CLINICAL_TRIALS withdrawal · 2016-06-21Clinical Trial Update: 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET) [Phase 2]
A Phase 2 trial of 90Y DOTA/Retinoic Acid for neuroblastoma and neuroendocrine tumors has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2016-06-13Clinical Trial Update: Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors [Phase 1]
A Phase 1 trial evaluating the combination of temsirolimus and vinorelbine ditartrate in adults with unresectable or metastatic solid tumors…
-
FDA approval · 2016-06-01FDA Approved: NETSPOT — Original Application (Advanced Accelerator Applications USA, Inc)
FDA approved NETSPOT (68Ga-DOTATATE) from Advanced Accelerator Applications USA, Inc for use as a diagnostic PET radiopharmaceutical. It is …
-
CLINICAL_TRIALS research · 2016-06-01Clinical Trial Update: Interest of Whole-body MRI Correlated to Spreading Sequences for Staging Neuroendocrine Tumors [NA]
This clinical trial update from CHU de Reims evaluates whole-body MRI correlated with spreading sequences for staging metastatic neuroendocr…
-
CLINICAL_TRIALS trial_result · 2016-05-30Clinical Trial Update: Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery [Phase 2]
Phase 2 trial evaluating the use of combination chemotherapy as first-line therapy for locally advanced or metastatic neuroendocrine tumors …
-
FDA approval · 2016-05-20FDA Approved: SANDOSTATIN LAR DEPOT — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Sandostatin LAR Depot (octreotide acetate) by Novartis, resulting in changes to the product …
-
CLINICAL_TRIALS trial_result · 2016-04-28Clinical Trial Update: Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor [Phase 3]
Phase 3 trial update studying octreotide acetate with interferon alfa-2b or bevacizumab in metastatic or locally advanced high-risk neuroend…
-
CLINICAL_TRIALS other · 2016-01-05Clinical Trial Update: Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors [Phase 2]
This clinical trial update describes a Phase 2 study of a recombinant anti-tumor and anti-virus protein for injection to treat advanced neur…
-
CLINICAL_TRIALS trial_result · 2015-12-29Clinical Trial Update: Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor [Phase 2]
Phase 2 study of pazopanib monotherapy in patients with unresectable, metastatic neuroendocrine tumor has completed.
-
CLINICAL_TRIALS trial_result · 2015-11-20Clinical Trial Update: Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET) [Phase 2]
Phase 2 clinical trial of MK-0646 in metastatic neuroendocrine tumors has completed and results were posted in 2015.
-
FDA approval · 2015-11-02FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
The FDA approved a supplemental application for Somatuline Depot (lanreotide acetate) submitted by Ipsen Biopharmaceuticals, Inc.
-
FDA approval · 2015-06-01FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
The FDA approved a supplemental application for Somatuline Depot (lanreotide acetate) filed by Ipsen Biopharmaceuticals, Inc., updating the …
-
CLINICAL_TRIALS trial_result · 2014-11-17Clinical Trial Update: Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors [Phase 2]
Phase 2 trial evaluating sorafenib tosylate in patients with progressive metastatic neuroendocrine tumors has completed; results were posted…
-
CLINICAL_TRIALS trial_result · 2014-09-25Clinical Trial Update: Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers [Phase 1, Phase 2]
This trial update reports termination of the Phase 1/2 study of JI-101 in advanced low-grade endocrine tumors, ovarian cancer, and KRAS-muta…
-
CLINICAL_TRIALS research · 2014-09-22Clinical Trial Update: A Clinical Trial With a New Needle Device Comparing Two Needles for EUS_FNA of Solid Lesions. [NA]
A clinical trial update describes a study comparing two needle devices for endoscopic ultrasound-guided fine-needle aspiration of solid lesi…